Supplementary data

Supplementary Table 1. Definition of an all-comers trial.

An all-comers trial was defined as one enrolling patients without the major exclusion criteria listed below.

- a Stenting for multiple lesions or vessels (>3 lesions or stents)
- b Low ejection fraction of left ventricular (<30 or 35%)
- c Haemodialysis
- d ST-segment elevation myocardial infarction
- e Non-ST-segment elevation acute coronary syndrome
- f Severely calcified lesion
- g Thrombotic lesion
- h Chronic total occlusion
- i In-stent restenosis
- j Saphenous vein graft
- k Arterial graft
- 1 Unprotected left main coronary artery
- m Bifurcated lesion with side branch (>2 mm) or requiring two stents
- n Aorto-ostial lesion
- o Long lesion with length over 30 mm

Supplementary Table 2. Search strategy.

PubMed		N of publications
#1	"Coronary Artery Disease"[Mesh]	64,648
#2	coronary[TIAB]	401,835
#3	#1 OR #2	412,330
#4	"Stents"[Mesh]	80,154
#5	stent*[TIAB]	103,181
#6	#4 OR #5	118,029
#7	#3 AND #6	34,902
#8	"randomized controlled trial"[Publication Type]	526,106
#9	"randomized controlled trials as topic"[MeSH Terms]	144,239
#10	#8 OR #9	662,528
#11	#7 AND #10	4,499

Embase

#1	'coronary artery disease'/exp	339,681
#2	coronary	737,700
#3	#1 OR #2	739,876
#4	'stent'/exp	175,261
#5	stent*	212,905
#6	#4 OR #5	215,209
#7	#3 AND #6	40,842
#8	#7 AND ('controlled clinical trial'/de OR 'randomized controlled trial'/de OR 'randomized controlled trial topic'/de)	3,948

Cochrane Library

#1	MeSH descriptor: [Coronary Artery Disease] explode all trees	6,525
#2	coronary:ti,ab,kw	56,852
#3	#1 or #2	56,852
#4	MeSH descriptor: [Stents] explode all trees	4,232
#5	stent*:ti,ab,kw	15,567
#6	#4 or #5	15,617
#7	#3 and #6	8,533
#8	#7 in Trials	8,509
#9	#8 not pubmed:an	4,204
#10	#9 not embase:an	1,692

Supplementary Table 3. Inclusion and exclusion criteria of the eligible and included trial.

Study name	All-comers trial	N of major exclusion criteria	Multiple lesions or vessels	Low EF	Haemodialysis	STEMI	NSTE-ACS	Severe calcification	Thrombus	сто	ISR	SVG	Arterial graft	Left main	Bifurcation	Aorto- ostium	Long lesion
TAXUS I	NO	14	Excluded	Excluded	Excluded	Excluded	Excluded	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Not reported	Excluded
SIRIUS	NO	13	Excluded	Included	Not reported	Excluded	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
TAXUS IV	NO	13	Excluded	Included	Excluded	Excluded	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
TAXUS VI	NO	12	Excluded	Excluded	Not reported	Excluded	Included	Excluded	Not reported	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Included
SIRTAX	YES	0	Included	Included	Not reported	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
TAXUS V	NO	11	Included	Included	Excluded	Excluded	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Included
ENDEAVOR II	NO	12	Excluded	Excluded	Not reported	Excluded	Excluded	Excluded	Not reported	Not reported	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
ENDEAVOR IV	NO	14	Excluded	Excluded	Not reported	Excluded	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
LEADERS	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
SPIRIT IV	NO	13	Excluded	Excluded	Not reported	Excluded	Included	Excluded	Not reported	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
ZEST	NO	3	Included	Included	Not reported	Excluded	Included	Included	Included	Included	Excluded	Included	Included	Excluded	Included	Included	Included
SORT OUT III	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
ISAR-TEST 4	NO	5	Included	Included	Included	Included	Included	Included	Included	Included	Excluded	Excluded	Excluded	Excluded	Included	Not reported	Included
COMPARE	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
PERSEUS	NO	7	Excluded	Not reported	Not reported	Excluded	Included	Included	Not reported	Not reported	Excluded	Excluded	Excluded	Not reported	Included	Not reported	Excluded
Kadota et al	NO	7	Excluded	Excluded	Excluded	Excluded	Included	Included	Included	Not reported	Excluded	Included	Included	Excluded	Included	Included	Excluded
PROTECT	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
SORT OUT IV	YES	0	Included	Not reported	Not reported	Included	Included	Not reported	Included	Included	Not reported	Included	Included	Included	Included	Not reported	Included
Resolute All Comer	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
ISAR-TEST 5	NO	5	Included	Included	Excluded	Included	Included	Included	Included	Included	Excluded	Excluded	Excluded	Excluded	Included	Included	Included
TWENTE	NO	2	Included	Included	Excluded	Excluded	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
ECO-PLEASANT	NO	5	Included	Excluded	Excluded	Excluded	Included	Included	Included	Included	Excluded	Not reported	Not reported	Excluded	Included	Not reported	Included
PLATINUM	NO	14	Included	Excluded	Not reported	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
COMPARE II	YES	0	Included	Not reported	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
SORT OUT V	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
RESET	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included

DUTCH PEERS	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
HOST-ASSURE	YES	1	Included	Included	Not reported	Included	Included	Not reported	Included	Included	Included	Included	Included	Included	Included	Included	Included
BASKET-PROVE II	NO	5	Included	Not reported	Not reported	Included	Included	Not reported	Included	Included	Excluded	Excluded	Excluded	Excluded	Included	Not reported	Included
PLATINUM PLUS	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
NEXT	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
PROMISE	NO	7	Included	Not reported	Excluded	Excluded	Included	Not reported	Included	Excluded	Excluded	Excluded	Not reported	Excluded	Excluded	Not reported	Included
SORT OUT VI	YES	0	Included	Not reported	Not reported	Included	Included	Not reported	Included	Included	Included	Included	Not reported	Included	Included	Included	Included
BIOSCIENCE	YES	0	Included	Not reported	Not reported	Included	Included	Not reported	Included	Included	Included	Included	Included	Included	Included	Included	Included
CENTURY II	NO	3	Included	Excluded	Excluded	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
EVOLVE II	NO	6	Included	Not reported	Not reported	Excluded	Included	Not reported	Not reported	Excluded	Excluded	Excluded	Excluded	Excluded	Not Reported	Not reported	Included
BIO-RESORT	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
SORT OUT VII	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
BIOFLOW-IV	NO	15	Excluded	Excluded	Excluded	Excluded	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded
BIONICS	NO	7	Excluded	Excluded	Excluded	Excluded	Included	Included	Not reported	Included	Included	Included	Included	Not reported	Excluded	Not reported	Excluded
HARMONEE	NO	10	Included	Excluded	Excluded	Excluded	Included	Included	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Not reported	Excluded
ReCre8	YES	1	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
SORT OUT VIII	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
BIOFLOW V	NO	10	Included	Excluded	Excluded	Excluded	Included	Included	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Excluded	Not reported	Included
DESSOLVE III	YES	1	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Not reported	Included
BIONYX	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
SORT OUT IX	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
TARGET All Comers	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included
TALENT	YES	0	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included	Included

All the eligible 49 trials enrolling non-specific population are listed. The included all-comers trials are highlighted in red. CTO: chronic total occlusion; EF: ejection fraction; ISR: in-stent restenosis; N: number; NSTE-ACS: non-ST-segment elevation acute coronary syndrome; STEMI: ST-segment elevation myocardial infarction; SVG: saphenous vein graft

Trial name	Device	N of patients	N of lesions	Mean age	Male (%)	Hypertension (%)	Diabetes (%)	Dyslipidaemia (%)	STEMI (%)	NSTE- ACS (%)	Prior MI (%)	Renal insufficiency (%)	N of lesions treated	Beta- blocker (%)	Statin (%)	ACEI/ ARB (%)	DAPT at one year (%)
SIRTAX	CYPHER	503	693	62	75.9	60	21.5	60.6	23.3	27.8	28.8		1.4				
SIRTAX	TAXUS Express	509	708	62	78.4	62.3	18.3	57	21.6	30.1	29.7		1.4				
LEADERS	BioMatrix	857	1,257	64.6	75	73.5	26	65.3	15.8	39.1	32.2		1.5				
LEADERS	CYPHER	850	1,215	64.5	74.6	72.7	22.5	68.2	16.5	39.2	32.6		1.4				
SORT OUT III	Endeavor	1,162	1,619	64.3	73.3	54	15	70	6	37.5	25						
	CYPHER	1,170	1,611	64.3	73.7	51	14	68	8.5	38.1	26						
COMPARE	XIENCE	897	1,286	62.9	69	46.5	17.1	49.8	26.8	33.6	15	3	1.4				70
	TAXUS Liberté	903	1,294	63.6	72.4	49.5	19	49.9	23.5	35.7	18	3	1.4				70
PROTECT	Endeavor	4,357	6,151	62.3	76.7	64.6	26.9	61.8	8.2	17.6	20		1.4				87
	CYPHER	4,352	6,140	62.1	76	63.4	28.4	62.8	8.8	17.1	21		1.39				88
SORT OUT IV	XIENCE/PROMUS	1,390	1,805	64.2	75.9	56.7	14	71.1	8.8	32.9	21.5		1.3				
	CYPHER	1,384	1,779	64	75.2	53.8	14.2	71.1	10.5	32.7	20.6		1.3				
Resolute All Comer	Resolute	1,140	1,661	64.4	76.7	71.1	23.5	63.9	34.5	19.4	28.9		1.46				
	XIENCE	1,152	1,705	64.2	77.2	71.3	23.4	67.7	33.7	18.9	30.4		1.48				
COMPARE II	Nobori	1,795	2,638	63	74.4	54.8	21.8		20.7	37.2	20.3	4.3	1.5				66.6
	XIENCE	912	1,387	62.7	74.3	56.3	21.6		21.6	36.2	18.8	4.4	1.5				65.9
SORT OUT V	Nobori	1,229	1,532	65	74.6	55.5	15.1	57.8	18.3	30.3	17.7		1.25				
	CYPHER	1,239	1,555	65.2	75.1	52.7	15.3	58.9	18.3	31	17.3		1.26				
RESET	XIENCE	1,597	1,967	68.9	77.5	79.5	45.5	74.5	6.5	11.3	29	2.1	1.23	36.8	77.4	61.8	11.1

	CYPHER	1,600	1,960	69.3	76.1	80.6	44.6	75.3	5.2	13.3	31	2.4	1.23	37.7	77.4	60.9	10.4
DUTCH PEERS	Resolute	906	1,205	64	73.4	55.2	18.4	46.1	19.3	39.6	23	4					
DUTCH PEEKS	XIENCE	905	1,166	65	72.6	53	17.3	47.5	21.5	36.8	21	3					
HOST-ASSURE	PROMUS	2,503	3,426	63.1	69.8	68.2	31.8	64	11.3	18.1	4.6	2.4		68.3	84.8	65.4	91.1
HUS1-ASSURE	Resolute	1,252	1,661	63.5	65.6	68.1	32	65.7	10.9	16.7	3.9	2.9		67.5	85.9	66.2	92.6
PLATINUM PLUS	PROMUS	1,952	3,289	65.7	77.7	68	29.1	63.4	8.7	28.1	21.7		1.6				59.4
FLATINOW FLUS	XIENCE	1,028	1,711	66.1	78.4	68.6	27.2	62.2	9.3	27.6	24.3		1.6				61.2
NEXT	Nobori	1,617	1,985	69.1	77	81.4	46.1	78.2	5.1	11.6	28	2.5	1.27				86.7
NEXI	XIENCE/PROMUS	1,618	1,947	69.3	77.4	81.8	45.7	78.1	4.4	11.1	28	2.6	1.24				87.5
SORT OUT VI	Resolute	1,502	1,883	65.7	76.2	59.7	17.6	59.3	19.6	31	18.7		1.3				
SORI OUI VI	BioMatrix	1,497	1,791	65.8	75.8	58.1	18	59.1	16.9	33.9	19.7		1.3				
BIOSCIENCE	Orsiro	1,063	1,594	66.1	77	68.5	24.2	67	19.8	34.4	21		1.5	47.3	53.6	25.9	83.4
BIOSCIENCE	XIENCE	1,056	1,545	65.9	77.3	66.9	21.7	67.8	18.6	33.9	19.3		1.46	45.4	54.2	26.6	82.1
	SYNERGY	1,172	1,532	64	72.1	44.4	17.3	36	32.2	37.5	16	3					85.5
BIO-RESORT	Resolute	1,173	1,580	63.6	72.3	47.2	17.9	38.4	27.8	41.7	21	3					86.3
	Orsiro	1,169	1,551	64.2	73.1	47	18	39.6	31.7	38.3	18	4					85.1
SORT OUT VII	Orsiro	1,261	1,590	66.1	74.9	58.1	18.7	57.6	21.3	30.8	17.4		1.3				
SORI OUT VII	Nobori	1,264	1,588	64.8	75.2	56.4	18.6	56.7	20.7	32.6	17.8		1.3				
ReCre8	Resolute	744	1,024	65.1	77.6	55.2	20	45.7	22.4	25	21.2						40.1
	Cre8	747	1,087	64.7	75.6	55.2	20.7	43.5	24.2	22.6	18.6						39.4
	SYNERGY	1,385	1,725	66	76.5	56.1	18.1	54			18						
SORT OUT VIII	BioMatrix	1,379	1,670	66	76.6	57.7	19	52.5			17						
DESSOLVE III	MiStent	703	1,037	66.4	70.3	72	26.6	60.8	14.7	44.2	27	7	1.49				

	XIENCE	695	993	66.3	73.8	75	27.1	60	15.7	43	28	7	1.44		
SORT OUT IX –	BioFreedom	1,572	1,966	66.4	77.5	56.8	16.7	52.8	23.3	32	14.7		1.3		
SORT OUT IX	Orsiro	1,579	1,985	66.1	77.3	53.8	16.6	49.2	25.1	32	15.2		1.3		
BIONYX -	Resolute Onyx	1,243	1,646	64.1	76.1	51.5	20.9	45.4	22.7	48.1	16.1	6.7		{	83.9
BIONYX -	Orsiro	1,245	1,593	63.9	76.1	53.2	20.1	46.4	27.2	43.9	15.6	6.7		8	82.2
TARGET All Comers -	FIREHAWK	823	1,221	64.9	78.1	59.9	24	53	8.4	35.4	21.7	5.5	1.5		
TARGET All Collers -	XIENCE	830	1,179	65.3	76.4	62.5	23	51.2	8.9	35.4	24.8	7	1.4		
TALENT —	Supraflex	720	1,046	66	75.8	65.3	21.8	61.8	16.5	43.1	18.9	2.8	1.45	 	
	XIENCE	715	1,030	65	76	66	24.9	60.2	16.4	40.3	17.9	2	1.44		

ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker; AHA/ACC: American Heart Association/American College of Cardiology; DAPT: dual antiplatelet therapy; LVEF: left ventricular ejection fraction; N: number; NSTE-ACS: non-ST-segment elevation acute coronary syndrome; STEMI: ST-segment elevation myocardial infarction

Supplementary Table 5. Definitions of myocardial infarction in the included trials.

Trial name	Study start year	Definition of spontaneous MI
SIRTAX	2003	Q or CKMB/cTn>2ULN
LEADERS	2006	ECG or (CK>2ULN + CKMB/cTn>1ULN)
SORT OUT III	2006	Clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰
COMPARE	2007	Clinical/ECG + CKMB/cTn>1ULN
PROTECT	2007	ECG or (clinical + CKMB/cTn>1ULN)
SORT OUT IV	2007	Clinical/ECG + cTn>1ULN [Universal definition]
Resolute All Comer	2008	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical] ⁷¹
COMPARE II	2009	Clinical/ECG + CKMB/cTn>1ULN
SORT OUT V	2009	Clinical/ECG + cTn>1ULN [Universal definition]
DUTCH PEERS	2010	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
HOST-ASSURE	2010	Clinical/ECG + cTn>1ULN [Universal definition]
PLATINUM PLUS	2010	(Q + CKMB/cTn>1ULN) or (ECG/clinical + CKMB/cTn>2ULN)
RESET	2010	CKMB/cTn>1ULN [ARC]
NEXT	2011	CKMB/cTn>1ULN [ARC]
SORT OUT VI	2011	Clinical/ECG + cTn>1ULN [Universal definition]
BIO-RESORT	2012	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
BIOSCIENCE	2012	Clinical/ECG + cTn>1ULN [Universal definition]
SORT OUT VII	2012	Clinical/ECG + cTn>1ULN [Universal definition]
ReCre8	2014	CKMB/cTn>1ULN [ARC]
SORT OUT VIII	2014	Clinical/ECG + cTn>1ULN [Universal definition]
BIONYX	2015	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
DESSOLVE III	2015	(Clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical]
SORT OUT IX	2015	Clinical/ECG + cTn>1ULN [Universal definition]
TARGET All Comers	2015	Clinical/ECG + cTn>1ULN [Universal definition]
TALENT	2016	Clinical/ECG + cTn>1ULN [Universal definition]
	. ~	

ARC: Academic Research Consortium; CKMB: creatine kinase myocardial band; Clinical: clinical findings related to myocardial infarction; cTn: cardiac troponin; ECG: ischaemic change in electrocardiograph; MI: myocardial infarction; Q: Q-wave detected on electrocardiograph; SCAI: Society for Cardiovascular Angiography and Interventions; ULN: upper limit of normal

Summary Table for the definition of spontaneous myocardial infarction

2003 -2007	N of trials
clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰	2
ECG or (CK>2ULN + CKMB/cTn>1ULN)	1
Q or CKMB/cTn>2ULN	1
Clinical/ECG + CKMB/cTn>1ULN	1
ECG or (clinical + CKMB/cTn>1ULN)	1
2008 - 2012	
clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰	5
(clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical] ⁷¹	3
CKMB/cTn>1ULN [ARC] ⁷²	2
(Q + CKMB/cTn>1ULN) or (ECG/clinical + CKMB/cTn>2ULN)	1
2013 - 2016	
clinical/ECG + cTn>1ULN [Universal definition] ⁷⁰	4
(clinical + Q + cTn/CK>1ULN) or (CK>2ULN + CKMB/cTn>1ULN) or CKMB/cTn>3ULN [Extended historical] ⁷¹	2
CKMB/cTn>1ULN [ARC] ⁷²	1

ARC: Academic Research Consortium; CKMB: creatine kinase myocardial band; Clinical: clinical findings related to myocardial infarction; cTn: cardiac troponin; ECG: ischaemic change on electrocardiograph; N: number; Q: Q-wave detected on electrocardiograph; SCAI: Society for Cardiovascular Angiography and Interventions; ULN: upper limit of normal

Supplementary Table 6. Definitions of cardiac death and clinically indicated target lesion revascularisation.

Trial name	Definition for cardiac death	Definition for clinically indicated TLR
SIRTAX	Definition not reported	ARC
LEADERS	ARC	ARC
SORT OUT III	ARC	N/A [#]
COMPARE	ARC	ARC
PROTECT	ARC	N/A#
SORT OUT IV	ARC	Clinically driven
Resolute All Comer	ARC	ARC
COMPARE II	ARC	ARC
SORT OUT V	ARC	Clinically driven
DUTCH PEERS	ARC	ARC
HOST-ASSURE	ARC	ARC
PLATINUM PLUS	Death due to MI; arrhythmia or conduction disturbance; deaths related to the procedure; stroke prior to hospital discharge; and death of unknown cause	ARC*
RESET	ARC	ARC
NEXT	ARC	ARC
SORT OUT VI	ARC	Clinically driven
BIO-RESORT	ARC	ARC*
BIOSCIENCE	ARC	ARC*
SORT OUT VII	ARC	Clinically driven
ReCre8	ARC	N/A [#]
SORT OUT VIII	ARC	Clinically driven
BIONYX	ARC	ARC
DESSOLVE III	ARC	ARC
SORT OUT IX	ARC	Clinical-driven
TARGET All Comers	Definition not reported	Definition not reported (ischaemia-driven)
TALENT	ARC	ARC

[#] Trial did not report the incidence of clinically indicated TLR. * The ARC definition was applied but quantitative coronary angiography was not performed at an independent angiographic core laboratory.

ARC: Academic Research Consortium; MI: myocardial infarction; TLR: target lesion revascularisation

Supplementary Table 7. Bias assessment of the included trials.

Trial name	RANDOM SEQUENCE GENERATION	ALLOCATION CONCEALME NT	BLINDING OF PARTICIPANT S AND PERSONNEL*	BLINDING OF OUTCOME ASSESSMENT	INCOMPLETE OUTCOME DATA	SELECTIVE REPORTING	OTHER BIAS
SIRTAX	Low	Low	High	Low	Low	Low	Low
LEADERS	Low	Low	High	Low	Low	Low	Low
SORT OUT III	Low	Low	High	Low	Low	Low	Low
COMPARE	Low	Low	High	Low	Low	Low	Low
PROTECT	Low	Low	High	Low	Low	Low	Low
SORT OUT IV	Low	Low	High	Low	Low	Low	Low
Resolute All Comer	Low	Low	High	Low	Low	Low	Low
COMPARE II	Low	Low	High	Low	Low	Low	Low
SORT OUT V	Low	Low	High	Low	Low	Low	Low
RESET	Low	Low	High	Low	Low	Low	Low
DUTCH PEERS	Low	Low	High	Low	Low	Low	Low
HOST-ASSURE	Low	Low	High	Low	Low	Low	Low
PLATINUM PLUS	Low	Low	High	Low	Low	Low	Low
NEXT	Low	Low	High	Low	Low	Low	Low
SORT OUT VI	Low	Low	High	Low	Low	Low	Low
BIOSCIENCE	Low	Low	High	Low	Low	Low	Low
BIO-RESORT	Low	Low	High	Low	Low	Low	Low
SORT OUT VII	Low	Low	High	Low	Low	Low	Low
ReCre8	Low	Low	High	Low	Low	Low	Low
SORT OUT VIII	Low	Low	High	Low	Low	Low	Low
DESSOLVE III	Low	Low	High	Low	Low	Low	Low
BIONYX	Low	Low	High	Low	Low	Low	Low
SORT OUT IX	Low	Low	High	Low	Low	Low	Low
TARGET All Comers	Low	Low	High	Low	Low	Low	Low
TALENT	Low	Low	High	Low	Low	Low	Low

* In all trials, the operator was not blinded while the assessors (clinical events committee, core laboratory, and statistician) were blinded. Awareness of the allocated stent possibly introduces a bias in the operator's procedure (e.g., lesion preparation, post-dilatation, etc.).

Supplementary Table 8. Performance of routine angiographic follow-up in the included trials.

Study name	Device	N of patients	Month at angio FU	N of patients undergoing angio FU	Patients with angio FU (%)	Month at 1Y TLR	1Y TLR (%)	Angio FU performed before 1Y result
	CYPHER	503	0	267	53.1%	10	5.8%	
SIRTAX	TAXUS Express	509	8	273	53.6%	12	10.2%	YES
	BioMatrix	857	0	168	19.6%	12	5.2%	VEC
LEADERS	CYPHER	850	9	167	19.6%	12	5.8%	YES
SORT OUT III	Endeavor	1,162	No oncio EU			12	5.3%	
SORTOUT III	CYPHER	1,170	No angio FU			12	1.4%	
COMPARE	XIENCE	897	No ongio EU			12	1.7%	
COMPARE	TAXUS Liberté	903	No angio FU			12	4.8%	
PROTECT	Endeavor	4357	No angio EU			12		
PROTECT	CYPHER	4,352	No angio FU			12		
SORT OUT IV	XIENCE/PROMUS	1,390	No angio FU			9	1.4%	
3081 001 10	CYPHER	1,384	No aligio PO			9	1.7%	
Resolute All Comer	Resolute	1,140	13	142	12.5%	12	3.9%	NO
Resolute All Comer	XIENCE	1,152	15	130	11.3%	12	3.4%	NO
COMDADE II	Nobori	1,795	No ongio EU			12	2.1%	
COMPARE II	XIENCE	912	No angio FU			12	1.8%	
SORT OUT V	Nobori	1,229	Na anaia EU			10	3.3%	
SORI OUT V	CYPHER	1,239	No angio FU			12	2.0%	
	Resolute	906				10	2.2%	
DUTCH PEERS	XIENCE	905	No angio FU			12	2.2%	
	PROMUS	2,503	No on 1 PH			10	1.3%	
HOST-ASSURE	Resolute	1,252	No angio FU			12	1.2%	
	PROMUS Element	1,952				10	2.0%	
PLATINUM PLUS	XIENCE	1,028	No angio FU			12	1.6%	
RESET	XIENCE	1,597	8	235	14.7%	- 12	2.9%	YES
KESE I	CYPHER	1,600	8	247	15.4%	12	3.7%	IES
NEVT	Nobori	1,617	0	227	14.0%	12	2.9%	VEC
NEXT	XIENCE/PROMUS	1,618	8	230	14.2%	12	2.9%	YES
SORT OUT VI	Resolute	1,502	No angio FU			12	3.5%	
30K1 001 VI	BioMatrix	1,497	No aligio PO			12	3.1%	
	SYNERGY	1,172					1.5%	
BIO-RESORT	Resolute	1,173	No angio FU			12	1.5%	
	Orsiro	1,169					1.5%	
BIOSCIENCE	Orsiro	1,063	No angio FU			12	3.4%	
BIOSCIENCE	XIENCE	1,056	No aligio 110			12	2.4%	
SORT OUT VII	Orsiro	1,261	No angio FU			12	2.0%	
SORT OUT VII	Nobori	1,264				12	2.9%	
ReCre8	Resolute	751	No angio FU			12		
AUCIU0	Cre8	751				12		
SORT OUT VIII	SYNERGY	1,385	No angio FU			12	2.3%	
SOKI OUT VIII	BioMatrix	1,379	The aligit I'U			12	2.5%	
BIONYX	Resolute Onyx	1,243	No angio FU			12	2.5%	
DIONIA	Orsiro	1,245	TNO aligio PU			12	2.0%	

DESSOLVE III	MiStent	703	No angio EU			12	2.6%	
DESSOLVE III	XIENCE	695	No angio FU			12	3.7%	
SODT OUT IN	BioFreedom	1,572	No oncio EU			12	3.5%	
SORT OUT IX	Orsiro	1,579	No angio FU			12	1.3%	
TARGET All Comers	FIREHAWK	823	13	71	8.6%	12	1.1%	NO
TARGET All Colliers	XIENCE	830	15	66	8.0%	12	2.3%	
TALENT	Supraflex	720	No oncio EU			12	2.7%	
IALENI	XIENCE	715	No angio FU			12	4.0%	

angio: angiography; FU: follow-up; N: number; TLR: target lesion revascularisation; Y: year

Supplementary Table 9. List of antiplatelet therapy regimens and bleeding event rates in the included trials.

Study name	Study start year	Device	N of patien ts	Recommended DAPT duration (months)	Recommended P2Y ₁₂ inhibitor	Percent of patients on DAPT at 1 year	Percent of patients with major bleeding at 1 year	Definition for bleeding event
		CYPHE R	503			Not reported	Not reported	NA
SIRTAX	2003	TAXUS Express	509	12	Clopidogrel	Not reported	Not reported	NA
		BioMatri x	857			Not reported	Not reported	NA
LEADERS	2006	CYPHE R	850	12	Clopidogrel	Not reported	Not reported	NA
SORT OUT		Endeavo	1,162			Not reported	Not reported	NA
ш	2006	CYPHE R	1,170	12	Clopidogrel	Not reported	Not reported	NA
		XIENCE	897			70.0	Not reported	NA
COMPARE	2007	TAXUS Liberté	903	12	Clopidogrel	70.0	Not reported	NA
PROTECT	2007	Endeavo r	4,357	3 to 12	Ticlopidine or clopidogrel	87.0	Not reported (only 2-year incidence reported)	TIMI
FROIECT	2007	CYPHE R	4,352	5 10 12		88.0	Not reported (only 2-year incidence reported)	TIMI
SORT OUT IV	2007	XIENCE / PROMU S	1,390	12	Clopidogrel or prasugrel	Not reported	Not reported	NA
		CYPHE R	1,384			Not reported	Not reported	NA
Resolute All	2000	Resolute	1,140			Not reported	Not reported	NA
Comer	2008	XIENCE	1,152	At least 6	Clopidogrel	Not reported	Not reported	NA
COMPARE	2000	Nobori	1,795	10		67.0	Not reported	NA
п	2009	XIENCE	912	12	Clopidogrel	66.6	Not reported	NA
SORT OUT	2000	Nobori	1,229	10		Not reported	Not reported	NA
V	2009	CYPHE R	1,239	12	Clopidogrel or prasugrel	Not reported	Not reported	NA
DUTCH	2010	Resolute	906	10		Not reported	Not reported	NA
PEERS	2010	XIENCE	905	12	Clopidogrel	Not reported	Not reported	NA
HOST-	2010	PROMU S	2,503	N. ((Double dose of clopidogrel or normal	91.1	1.1	PLATO
ASSURE	2010	Resolute	1,252	Not reported	dose of clopidogrel plus cilostazol	92.6	1.3	PLATO
PLATINUM PLUS	2010	PROMU S Element	1,952	At least 6	Clopidogrel or prasugrel	59.4	Not reported	NA
1205		XIENCE	1,028			61.2	Not reported	NA
RESET	2010	XIENCE	1,597	At least 3	Ticlopidine or clopidogrel	89.0	1.0	TIMI
RESET	2010	CYPHE R	1,600	At loast 5	The optimie of elophologies	90.0	1.3	TIMI
		Nobori	1,617			86.7	1.1	TIMI
NEXT	2011	XIENCE / PROMU S	1,618	At least 3	Ticlopidine or clopidogrel	87.5	0.9	TIMI
SORT OUT		Resolute	1,502		Clopidogrel, ticagrelor or	Not reported	Not reported	NA
VI	2011	BioMatri x	1,497	12	prasugrel	Not reported	Not reported	NA
		SYNER Y	1,172			85.5	Not reported	NA
BIO- RESORT	2012	Resolute	1,173	6 to 12	Clopidogrel, ticagrelor or prasugrel	86.3	Not reported	NA
		Orsiro	1,169		r87.07	85.1	Not reported	NA
BIOSCIENC		Orsiro	1,063		Clopidogrel, ticagrelor or	83.4	2.9	BARC 3-5
E	2012	XIENCE	1,056	12	prasugrel	82.1	2.6	BARC3-5
SORT OUT VII	2012	Orsiro	1,261	12	Clopidogrel, ticagrelor or prasugrel	Not reported	Not reported	NA

		Nobori	1,264			Not reported	Not reported	NA
D.C.se	2014	Resolute	751	1 for Tn negative /	Clopidogrel, ticagrelor or	40.1	1.7	BARC 3-5
ReCre8	2014	Cre8	751	12 Tn positive	prasugrel	39.4	1.6	BARC 3-5
SORT OUT	2014	SYNER Y	1,385	12	Clopidogrel, ticagrelor or	Not reported	Not reported	NA
VIII	2014	BioMatri x	1,379	12	prasugrel	Not reported	Not reported	NA
BIONYX	2015	Resolute Onyx	1,243	At least 6 for stable	Clopidogrel, ticagrelor or	83.9	2.5	BARC 3 or 5 or any TIMI
BIONYA	2015	Orsiro	1,245	coronary disease / 12 for ACS	prasugrel	82.2	2.7	BARC 3 or 5 or any TIMI
DESSOLVE	2015	MiStent	703	At least 6	Clopidogrel, ticagrelor or	Not reported	Not reported	NA
ш	2015	XIENCE	695	At least o	prasugrel	Not reported	Not reported	NA
SORT OUT	2015	BioFree dm	1,572	6 for stable coronary disease /	Clopidogrel, ticagrelor or	Not reported	Not reported	NA
IX	2013	Orsiro	1,579	12 for ACS	prasugrel	Not reported	Not reported	NA
TARGET All	2015	FIREHA WK	823	At least 6 for stable coronary disease /	Clopidogrel, ticagrelor or	Not reported	Not reported	NA
Comers	2015	XIENCE	830	12 for ACS	prasugrel	Not reported	Not reported	NA
TALENT	2016	Suprafle x	720	At least 6 for stable coronary disease /	Clopidogrel, ticagrelor or	Not reported	Not reported	NA
IALENI	2010	XIENCE	715	12 for ACS	prasugrel	Not reported	Not reported	NA

ACS: acute coronary syndrome; DAPT: dual antiplatelet therapy; N: number; NA: not applicable; TIMI: Thrombolysis In Myocardial Infarction; Tn: troponin

BioFreedom[™] (Biosensors, Singapore)

BioMatrix TM (Biosensors, Singapore)

Cre8TM (Alvimedica, Istanbul, Turkey)

CYPHER® (Cordis Santa Clara, CA, USA)

Endeavor® (Medtronic, Minneapolis, MN, USA)

FIREHAWK® (MicroPort, Shanghai, China)

MiStent® (Micell Technologies, Durham, NC, USA)

Nobori® (Terumo Corp., Tokyo, Japan)

Osiro (Biotronik, Berlin Germany)

PROMUS™ (Boston Scientific, Marlborough, MA, USA)

Resolute[™] (Medtronic, Minneapolis, MN, USA)


Resolute OnyxTM (Medtronic, Minneapolis, MN, USA)

Supraflex[™] (Sahajanand Medical Technologies, Mumbai, India)

SYNERGYTM (Boston Scientific, Marlborough, MA, USA)


TAXUS Express (Boston Scientific, Marlborough, MA, USA)


TAXUS[™] Liberté[™] (Boston Scientific, Marlborough, MA, USA) XIENCE® (Abbott Laboratories, Abbott Park, IL, USA)




Supplementary Figure 1. Study selection process.


N: number; RCT: randomised controlled trial










Study start year	arms	N of patients				In	cidence (%) [95%CI]
2003-2007	10	9600		1.63 [1.27, 1.99]			
2008-2012	19	23135		1.27 [1.09, 1.45]			
2013-2016	12	11787					1.14 [0.86, 1.41]
Total	0 + 0.00 f + 9				-		1.32 [1.17, 1.47]
U + 877638, 0* + 40,	p+0.00(1 + 8	ins.	-		1		
			0.5	1	1.5	2	
				Incide	nce (%)		



Study start year	study	N of patients							ncidence (%) [95%CI]
2003-2007	10	9600		-		-	-		4.32 [2.57, 6.08]
2008-2012	19	23135	-4	-					2.43 [2.08, 2.79]
2013-2016	10	10296	-						2.60 [2.01, 3.19]
Total				-					2.96 [2.41, 3.51]
Q + 21901.10.0*+ 34	(3+500,F+1	a y s		- 1	- 1	- 1		_	
			2	3	4	5	6	7	
				le le	ncider	ce (*	6)		









Study start year	study arms	N of patients							Inc	cidence (%) [95%CI]
2003-2007	10	9511		-		•	_	-		5.56 [4.60, 6.51]
2008-2012	10	11185		-	-	-				4.74 [4.23, 5.26]
Total 0 - 408723. d - 18. p - 0.00. f - 19.75			-	-	-				5.15 [4.59, 5.71]	
Q + 4087.23, 8* + 18,	p+0.00, r + M	175	1	1	-	1	-	1	_	
			4	4.5	5	5.5	6	6.5	7	
					Inci	dence	(%)			

Study start year	study arms	N of patients					ân	ciden	ice (%) [95%	cıj
2003-2007	6	4405		-			-	8	.81 [7.15, 10	.46]
2008-2012	6	6921			-	-	_		8.41 (6.85, 9	.97]
Total 0 - 31/7.07. d - 11.		-		5	_	_	-	8	61 [7.51, 9	.70]
Q = 3917.07, df = 11.	p+0.00, r + #	ins.		1	- 1	-		_		
			6	7	8	9	10	11		
				- 3	Incider	ice (%	•)			

Study start year	N of study arms	N of patients		Incidence (%) [95%CI]
2003-2007	10	9511		9.05 [6.72, 11.38]
2008-2012	8	9387		7.44 [6.25, 8.62]
Total Q = 11087.71, df = 17, p = 0.00, f ² = 16.9%		8.75		8.33 [6.92, 9.74]
			6 7 8 9 10 12	
			Incidence (%)	



Supplementary Figure 2. The results of sensitivity analysis.



Supplementary Figure 3. Temporal trends of all-cause death and non-cardiac death.